Shanghai Fosun Pharmaceutical : ANNOUNCEMENT RESULT OF THE PUBLIC ISSUANCE OF CORPORATE BONDS (FIRST TRANCHE) IN 2021 （H股）

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥（集 團）股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

ANNOUNCEMENT

RESULT OF THE PUBLIC ISSUANCE OF CORPORATE BONDS

(FIRST TRANCHE) IN 2021

Reference is made to the announcements of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company") dated 29 March 2019 and 22 April 2020 (the "Announcements"), the circular dated 26 April 2019 (the "Circular") and the poll results announcement dated 25 June 2019 in relation to, among other things, the proposed issue of Corporate Bonds to professional investors in the PRC. Unless otherwise specified, capitalized terms used herein shall have the same meaning ascribed to them in the Circular and Announcements.

According to the "Approval of the Public Issuance of the Corporate Bonds to the Professional Investors by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (Zheng Jian Xu Ke [2020] No. 701)" issued by the CSRC in April 2020, the registration application of the Company for public issuance of the Corporate Bonds to professional Investors in the principal amount of up to RMB5 billion was approved. Pursuant to the "Issuance Announcement on the Public Issuance of Corporate Bonds of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (First Tranche) in 2021", the base issue size of the first tranche of the public issuance of Corporate Bonds in 2021 (the "Current Tranche of Corporate Bonds") shall be in the amount of up to RMB1 billion (inclusive), and the over-allotment size shall be in the amount of up to RMB1 billion (inclusive). The Current Tranche of the Corporate Bonds shall be issued in two types, the term of type 1 corporate bonds issued under the Current Tranche Corporate Bonds (the "Type 1") shall be 4 years, the Company shall be entitled to adjust the coupon rate and the investors shall be entitled to sell back the Corporate Bonds at the end of the second year during the term of the Type 1; the term of type 2 corporate bonds issued under the Current Tranche Corporate Bonds (the "Type 2") shall be 5 years, the Company shall be entitled to adjust the coupon rate and the investors shall be entitled to sell back the Corporate Bonds at the end of the third year during the term of the Type 2.

1

The issuance of Current Tranche of the Corporate Bonds was closed on 2 February 2021, by offline placing to professional investors through book building process, of which the total principal amount of Type 1 is RMB1.6 billion at the final coupon rate of 3.98%, and the issuance of Type 2 was cancelled.

The directors, supervisors, senior management, shareholders with more than 5% shareholding and other related parties of the Company did not participated the subscription of the Current Tranche of Corporate Bonds.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the People's Republic of China

3 February 2021

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non- executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

• for identification purposes only

2